JACK KAVANAUGH, M.D., D.D.S., M.B.A.

Chairman, Acting CEO

Dr. Kavanaugh’s background as a physician and a business executive has led to the development of an unusual skill set. That, coupled with a talent for discerning what’s truly innovative and an ability to accurately gauge the commercial potential of a given research project, start-up or company, has resulted in an impressive array of business accomplishments. He has developed and managed companies at every stage – from inception to successful sale – creating industry-leading products and investor profits. Although his work spans a number of industries, he has focused on the health and science technology sector, capitalizing on his background in medicine and business to lead mergers, acquisitions, turnarounds, and corporate strategic development and initiatives. Dr. Kavanaugh holds D.D.S., M.B.A. and B.A. degrees from UCLA, and an M.D. from U.S.C. He completed his residency in ophthalmology at UCLA’s Jules Stein Institute, where he later taught surgery as a part-time visiting professor. Besides his chairmanship at Novonco, Kavanaugh is also Chairman and co-founder of Nanotech Energy, which is moving the world’s leading edge research on graphene supercapacitors from the laboratory to the marketplace; and SuperMetalix, Inc., which is developing a cost-efficient product that is more than twice as hard as carbide. Last May, he also accepted chairmanship of Orbsen Therapeutics, an Irish-based company that has developed a leading platform stem cell technology. Among Dr Kavanaugh’s business accomplishments: As CEO and Chairman of ZetaRx Biosciences, Inc, he successfully combined the intellectual property from three globally-recognized health care and research institutions, assembled a highly respected management team, and lead the development of the FDA clinical trial strategy. In late 2013, ZetaRx was sold, becoming the core of Juno Therapeutics, which went on to have the largest biotech IPO of 2014, attaining a market cap of approximately $6 billion. Recently, Juno reported 91% clinical trial complete remission of terminal cancer patients treated with their immunotherapy. Prior to that, he served as Chairman of Calhoun, a biotech firm that developed the world’s only light adjustable intraocular lens for cataract surgery. Its industry-leading product has already completed FDA Stage III clinical trials. In 1996, Dr. Kavanaugh founded Amerident, a health care service provider, serving as Chairman and CEO. Under his tenure, the company organically grew its employee-ranks to over 600 by 1999, when it was sold to a public company. Amerident received over 30 community service awards and a state congressional medal of honor for its work with infants. As founder, Chairman and CEO of Team Global, Dr. Kavanaugh was responsible for taking the company public, helping guide and create value as the public share price rose from an initial investor cost of 11 cents per share to approximately $27 per share. He was until recently a member of the board of Materia, a company that holds more than 300 patents and is instrumental in the production of over 100 pharmaceutical products.


JING HUANG, Ph.D.

Scientific Founder, Chair of Scientific Advisory Board

Jing.png

Jing Huang has invented the DARTS (Drug Affinity Responsive Target Stability) method for identifying the direct binding target(s) of small molecules. DARTS introduces a new paradigm for drug target identification and small molecule mechanistic studies, as well as enabling the development of drugs against traditionally undruggable targets. Jing received her B.S. in Genetics from Fudan University in Shanghai, China; Ph.D. in Biochemistry and Molecular Biology from USC School of Medicine, Los Angeles, CA; and postdoctoral in Chemistry and Chemical Biology at Harvard University, Cambridge, MA. Dr. Jing Huang is a world-renowned scientist and Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA, and a member of the Molecular Biology Institute and Jonsson Comprehensive Cancer Center at UCLA. Research in her lab focuses on the molecular regulation of longevity and the development of anti-aging drugs that can be used to prevent and/or treat age-related diseases, particularly cancer, heart disease, and neurodegenerative diseases. Dr. Huang is the scientific founder of two companies, LongLifeRx and DARTS Sciences.

Link to Jing Huang Lab webpage:
http://labs.pharmacology.ucla.edu/huanglab/ 
http://www.jinghuanglabucla.com/


BRETT LOMENICK, Ph.D.

Scientific Advisory Board, Chief Operating Officer

Dr. Lomenick received his B.S. degree in Molecular Biology from the University of Tennessee at Chattanooga in 2007 and his Ph.D. in Molecular and Medical Pharmacology at UCLA under the mentorship of Dr. Jing Huang in 2013. As a graduate student, Dr. Lomenick was a trainee of the NIH-UCLA Chemistry-Biology Interface Training Grant and was also awarded a Dissertation Year Fellowship by UCLA. In the laboratory of Dr. Huang, Dr. Lomenick spearheaded the development of the Drug Affinity Responsive Target Stability (DARTS) method for small molecule target identification, which can identify the direct binding protein targets of any small molecule drug using the native, unmodified compounds. After receiving his Ph.D., he continued his postdoctoral studies in the lab of Dr. Huang as a fellow of the NIH-UCLA Tumor Immunology Training Grant to further develop DARTS and to investigate the mechanisms of action of their newly discovered anti-aging compounds. His advanced gel-free DARTS platform will now be used at DARTS Sciences to perform unbiased, proteome-wide target identification for your compounds of interest.


ROBERT SNUKAL

Member, Board of Directors

Mr. Robert M. Snukal has been Chief Executive Officer and President of National Quality Care Inc. since December 24, 2005. Mr. Snukal has served as Chief Executive Officer for several convalescent hospitals and rehabilitation centers including Fountain View Convalescent Hospital, Sycamore Park, Montebello, Rio Hondo, Elmcrest and Alexandra Convalescent Hospitals as well as Hancock Park Rehabilitation Centre, Hancock Park Retirement Centre and Locomotion Therapy Company. Mr. Snukal served as Chief Executive Officer and President of Skilled Healthcare Group, Inc. (formerly Fountain View, Inc.) from August 1, 1997 to 2002. He has been a Member of the Board of Directors of ZetaRx Biosciences, Inc. since 2010, Nanotech Energy, Inc. since 2015, SuperMetalix, Inc. since 2015 and LonglifeRX, Inc. since 2016. He has been a Director of Arrogene, Inc. since May 13, 2016. He has been a Director of National Quality Care Inc. since February 11, 2003. From August 1, 1997 to 2002, he served as a Member of the Board of Directors of Fountain View, Inc. He served as a Member of the Board of Directors of Skilled Health Care Inc. from 2002 to 2005 and Quantason, Inc. from 2005 to 2014. He served as a Member of the Board of Directors at the not-for-profit Pacific Asia Museum in Pasadena, California from 2004 to 2010. He was Canada Council Fellow, and has authored several publications. Mr. Snukal was a Lecturer and an Assistant Professor in several universities including the University of British Columbia, the University of Sussex in England and the University of Calgary. He is the author of High Talk: The Philosophical Poetry of W.B. Yeats published by Cambridge University Press in 1974. Mr. Snukal is a graduate of the University of Manitoba where he earned a Bachelor of Arts (1964) and Masters of Arts in English Literature (1966).